@article{ref1,
title="Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample",
journal="International journal of psychiatry in clinical practice",
year="2009",
author="Irene, R. and Luis, M.A. and Helena, D.-c. and David, P. and Ramon, D.J. and Inmaculada, G.",
volume="13",
number="2",
pages="100-108",
abstract="OBJECTIVEs. To evaluate the efficacy and safety of switching from a selective serotonin reuptake inhibitor (SSRI) to duloxetine in non- or partial responders. <br><br>METHODS. This is a post-hoc analysis of the pooled data of the Spanish sample from an open-label, multicentre study. Additionally, a 6-month continuation safety phase was performed. <br><br>RESULTS. A total of 156 patients were switched to duloxetine from SSRIs. More than 83% completed the acute phase, of whom 75% went into the continuation phase. At baseline, the mean duration of SSRI treatment was 71.2 weeks and the HAM-D17 mean score was 22.4. In the acute-phase, symptoms severity significantly improved after 10 weeks of duloxetine treatment as measured by mean change from baseline in HAM-D 17 total score (-10.5; P < 0.001) and all secondary efficacy measures, including painful symptoms. Response (≥50% decrease in HAM-D 17 total score) and remission rates (HAM-D17 total score ≤7) were 52.9 and 27.7%, respectively. The most common adverse events reported in both phases were headache (11.5% [acute]; 6.1% [continuation]) and nausea (6.4% [acute]; 5.1% [continuation]). In a population of Spanish SSRI non- and partial responders, switch to duloxetine was associated with significant improvement in emotional and painful symptoms of depression. Duloxetine was well tolerated and safe during both phases. © 2009 Informa UK Ltd.<p /><p>Language: en</p>",
language="en",
issn="1365-1501",
doi="10.1080/13651500802578975",
url="http://dx.doi.org/10.1080/13651500802578975"
}